Thermo Fisher Completes One Lambda Purchase | GenomeWeb

NEW YORK (GenomeWeb News) – Thermo Fisher Scientific has completed its acquisition of transplant diagnostics firm One Lambda for $925 million.

One Lambda, which had 2011 revenues of around $182 million, will become part of Thermo Fisher's Specialty Diagnostics Segment. The Canoga Park, Calif.-based firm develops tests that are used by transplant centers for tissue typing, mainly for determining compatibility between donors and recipients and for detecting the presence of antibodies that can result in transplant rejection.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Cell this week: proteomic consequences of genomic changes in ovarian cancer, Human SRMAtlas, and more.

At Nature, John Wilbanks and Eric Topol call for openness in health data.

Law.com predicts that genomic and genetic testing will become common in toxic tort cases.

A Pew Research Center report finds that most Americans are wary of using technologies like gene editing to enhance human abilities.